

**SinuSys Announces Appointment of Bradley Marple, MD  
to join Scientific Advisory Board**

*Nationally recognized key opinion leader (KOL) physician to advise on research and clinical development activities*

**Palo Alto, CA** – SinuSys, a sinus health company, announced today the appointment of Bradley Marple, MD to join the company’s Scientific Advisory Board. SinuSys’ recently completed financing enabled the company to initiate First in Man studies, which commenced in late April of 2012.

“We are honored to have attracted Dr. Marple to our Scientific Advisory Board” said Thomas Schreck, chief executive officer of SinuSys. “Brad is a nationally recognized Ear, Nose and Throat (ENT) physician and key opinion leader and will be instrumental in advising on our research, clinical development and regulatory activities.”

Dr. Marple has a wealth of experience in the field of otolaryngology. After graduating with honors from the University of Oklahoma, College of Medicine, in 1988, he completed an Otolaryngology residency at the University of Texas Southwestern Medical Center at Dallas. Dr. Marple has been a part of the faculty at the University of Texas Southwestern since 1994 and has served as Vice Chairman of the Department of Otolaryngology since 2001. He has also served as Chief of Otolaryngology at Parkland Memorial Hospital and Dallas Veterans Administration Hospital.

Dr. Marple’s research interests have focused on inflammatory disorders of the paranasal sinuses. He has concentrated on the use of leukotriene inhibitors in the treatment of inflammatory sinonasal disease as well as surgical and medical treatments for allergic fungal sinusitis. Dr. Marple also serves on the Editorial Advisory Board for “Respiratory Reviews” and is a reviewer for the American Journal of Rhinology, Otolaryngology Head and Neck Surgery, Head and Neck, and Laryngoscope. Additionally, he is heavily involved with the American Academy of Otolaryngic Allergy and also serves as a Senior Examiner for the American Board of Otolaryngology.

“I am excited to be joining the Scientific Advisory Board at SinuSys” said Dr. Marple. “Sinusitis is a very large, unmet medical need, with limited good options for the physician and patient. I believe SinuSys has the right approach with a relatively simple, office-based procedure that can easily be adopted and potentially make a big difference for this patient population.”

**About Sinusitis**

Chronic sinusitis affects more than 31 million people in the United States. It is more prevalent than heart disease and asthma and has a greater impact on patients’ quality of life than chronic back pain or congestive heart failure. The majority of patients with

**Date:** June 6, 2012  
**For Immediate Release**



**Contact:** Ashwin Pushpala  
(408) 483-6518

chronic sinusitis are treated with oral antibiotics and/or nasal steroids, which can increase the risk of antibiotic resistance and cause unwanted side effects such as epistaxis (nose bleeds), nasal ulcers, and nasal and oral infections. The most effective treatments are Functional Endoscopic Sinus Surgery (FESS) and balloon dilation at high pressures, which are known to cause significant patient discomfort and are conducted in a surgical suite under general anesthesia or IV sedation. The United States healthcare system currently spends more than \$8 billion annually on improving the health of patients with sinus conditions.

### **About SinuSys**

SinuSys Corporation ([www.sinusys.com](http://www.sinusys.com)) is a medical device company focused on developing new therapies to improve the sinus health of patients with chronic sinusitis. The company's initial focus is a self-dilating medical device inserted at the ostium of the maxillary sinus, which restores functional sinus drainage and ventilation while minimizing patient discomfort. The device does not require external hardware or physician training to support expansion, and can be placed in an office-based setting, mitigating the need for general anesthesia and invasive sinus surgery and reducing patient recovery time. The device utilizes SinuSys' proprietary osmotic technology to enable an effective out-patient procedure that can be performed by Ear, Nose and Throat (ENT) physicians with minimal additional training.